Date published: 2026-5-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

KV4.1 Inhibitors

KV4.1 Inhibitors are a class of chemical compounds specifically designed to target and inhibit the KV4.1 potassium channel, a member of the voltage-gated potassium channel family that plays a crucial role in regulating the electrical excitability of cells, particularly in the nervous and cardiovascular systems. The KV4.1 channel is responsible for conducting potassium ions out of the cell in response to changes in membrane potential, a process essential for the repolarization phase of the action potential. By modulating the flow of potassium ions, KV4.1 channels help to control the duration and frequency of action potentials, influencing cellular excitability and signal transmission. KV4.1 Inhibitors function by binding to specific sites on the KV4.1 channel, either within the pore-forming region or at regulatory sites, thereby blocking or altering the channel's ability to conduct potassium ions. This inhibition can affect the channel's gating properties, such as the voltage sensitivity or the speed of activation and inactivation, ultimately reducing or completely preventing the flow of potassium ions through the channel.

The chemical properties of KV4.1 Inhibitors are critical for their ability to effectively target and modulate the function of the KV4.1 channel. These inhibitors are often designed to interact specifically with the unique structural features of the KV4.1 channel, such as the selectivity filter, voltage-sensing domains, or other key regions involved in channel gating. The molecular structure of these inhibitors may include hydrophobic or aromatic groups that fit snugly within the hydrophobic pockets of the channel, as well as polar or charged groups that can form hydrogen bonds or ionic interactions with specific amino acids lining the channel pore or gating regions. Additionally, the solubility, stability, and bioavailability of these inhibitors are optimized to ensure they can efficiently reach and act on the KV4.1 channels in their native cellular environment. The binding kinetics, including the association and dissociation rates, play a crucial role in determining the potency and duration of the inhibitory effect, as they influence how long the inhibitor remains bound to the channel and how effectively it can block potassium ion flow. By studying the interactions between KV4.1 Inhibitors and the channel, researchers can gain deeper insights into the biophysical mechanisms that govern ion channel function and the broader role of KV4.1 in cellular excitability and signal propagation.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Fluorouracil

51-21-8sc-29060
sc-29060A
1 g
5 g
$37.00
$152.00
11
(1)

This compound might downregulate KV4.1 by interfering with the transcriptional machinery, leading to impaired synthesis of mRNA encoding the channel.

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$74.00
$243.00
$731.00
$2572.00
$21848.00
53
(3)

By binding to DNA sequences, Actinomycin D can halt the transcription initiation, leading to a decrease in KV4.1 channel protein synthesis.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Bortezomib could reduce KV4.1 expression by stabilizing negative regulators of transcription, which might otherwise be degraded by the proteasome.

Chetomin

1403-36-7sc-202535
sc-202535A
1 mg
5 mg
$186.00
$674.00
10
(1)

Chetomin may decrease KV4.1 expression by disrupting transcription factor binding, essential for the expression of the channel.

5-Aza-2′-Deoxycytidine

2353-33-5sc-202424
sc-202424A
sc-202424B
25 mg
100 mg
250 mg
$218.00
$322.00
$426.00
7
(1)

By inducing DNA hypomethylation, Decitabine could lead to the silencing of the KCND1 gene promoter, resulting in decreased synthesis of KV4.1.

Mithramycin A

18378-89-7sc-200909
1 mg
$55.00
6
(1)

This antibiotic could downregulate KV4.1 by preventing specific transcription factors from binding to the DNA, thereby reducing channel expression.

Valproic Acid

99-66-1sc-213144
10 g
$87.00
9
(1)

As a histone deacetylase inhibitor, Sodium valproate may promote a chromatin state that is less conducive to the transcription of the KCND1 gene.

Tamoxifen

10540-29-1sc-208414
2.5 g
$272.00
18
(2)

Tamoxifen may decrease KV4.1 expression by altering the transcriptional activity of estrogen receptors, which can influence the KCND1 gene promoter.

Triptolide

38748-32-2sc-200122
sc-200122A
1 mg
5 mg
$90.00
$204.00
13
(1)

Triptolide could inhibit the transcription of KCND1 by disrupting the activity of transcription factors necessary for KV4.1 expression.

Withaferin A

5119-48-2sc-200381
sc-200381A
sc-200381B
sc-200381C
1 mg
10 mg
100 mg
1 g
$130.00
$583.00
$4172.00
$20506.00
20
(1)

Withaferin A could downregulate KV4.1 by inhibiting the activation of NF-kB, a transcription factor that may control the expression of the KV4.1 channel.